TICKERNERD
Menu
ENGNENGNHealthcare · Biotechnology

ENGN Stock Forecast: enGene Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$1.53
−3.16% on the day

The 9 Wall Street analysts covering enGene Therapeutics, Inc. hold a median 12-month price target of $4 — +161.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 28 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$103.9M
Ticker Nerd rank
18/ 100
Median analyst target
$4.00
Analysts covering
9
Revenue$0.0
Operating income−$34.0M
Net income−$32.5M
Free cash flow−$18.9M
Quarterly, 8 quarters to 31 July 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.2%
1M
−21.5%
YTD
−83.1%
1Y
−79.1%
From 52W high
−87.4%
From 52W low
+6.3%
$1
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ENGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores enGene Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
18/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
73
Accruals
62
Quality
52
Volatility
43
Growth
40
Revisions
26
Issuance
19
Value
12
Momentum
9

Size (73): Smaller than most of the companies we track.

Momentum (9): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ENGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ENGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$2$4$6$8$10$12Jan 26Apr 26Jul 26Oct 26ENGNHigh $5.00Median $4.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
3 Buy6 Hold0 Sell
Low $2.00Median $4.00High $5.00

The green dot is the last close — the median target sits +161.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Sept 2026CitizensReiteratesMarket Perform—
8 Sept 2026HC Wainwright & Co.ReiteratesBuy$4.00
18 June 2026Morgan StanleyDowngradeUnderweight—
18 June 2026Morgan StanleyDowngradeUnderweight—
16 June 2026HC Wainwright & Co.MaintainsBuy$6.00 → $4.00
16 June 2026HC Wainwright & Co.MaintainsBuy—
14 May 2026UBSMaintainsNeutral—
8 May 2026CitizensDowngradeMarket Perform—
8 May 2026GuggenheimDowngradeNeutral—
8 May 2026HC Wainwright & Co.MaintainsBuy—
8 May 2026Piper SandlerDowngradeNeutral—
8 May 2026Wells FargoDowngradeEqual-Weight—
13 Apr 2026WBB SecuritiesInitiatesBuy—
11 Mar 2026OppenheimerMaintainsOutperform—
9 Mar 2026HC Wainwright & Co.ReiteratesBuy—
12 Nov 2025CitizensMaintainsMarket Outperform—
12 Nov 2025Morgan StanleyMaintainsOverweight—
12 Nov 2025OppenheimerReiteratesOutperform—
12 Nov 2025UBSMaintainsNeutral—
12 Sept 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ENGN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ENGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, enGene Therapeutics, Inc. returned −79.1% against +13.1% for the S&P 500, dividends included.

ENGN vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26ENGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ENGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
6
Fundamentals

enGene Therapeutics, Inc. (ENGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 82% of US stocks

Price / sales
—
Price / book
0.5×

Cheaper than 84% of US stocks

EV / EBITDA
0.9×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−60.5%

Higher than 19% of US stocks

Return on assets
−32.0%

Higher than 13% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

enGene Therapeutics, Inc. (ENGN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • enGene Therapeutics, Inc. has a market value of $103.9M and an enterprise value of −$129.2M.

  • Revenue in the twelve months to 31 July 2026: $0.0.

  • Net income over the same four quarters: −$130.4M.

  • Free cash flow in the twelve months to 31 July 2026: −$104.0M.

  • Shares outstanding: 67.0M.

  • Trailing P/E: −0.7×; forward P/E: −1.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • enGene Therapeutics, Inc. employs 81 people.

Statement figures: company filings via Twelve Data, four quarters to 31 July 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

ENGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ENGNenGene Therapeutics, Inc.$103.9M18
VTVTvTv Therapeutics, Inc.$101.3M77
VANIVivani Medical, Inc.$102.8M48
NERVMinerva Neurosciences, Inc.$103.0M35
LENZLENZ Therapeutics, Inc.$100.4M22
UNCYUnicycive Therapeutics, Inc.$100.4M43
PMVPPMV Pharmaceuticals, Inc.$104.2M77

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own enGene Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ENGN news & analysis

enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path

MarketBeat · 16 Oct 2026positive

enGene used a company webinar to present preclinical findings on investigational non-viral gene therapy detalimogene voraplasmid combined with a polidocanol surfactant bladder rinse. Community urologists also discussed treatment burdens for people with high-risk NMIBC.

Why it matters — The webinar outlined preclinical data and a 2027 update path for ENGN’s investigational bladder cancer therapy.

enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript

Seeking Alpha · 15 Oct 2026neutral

A Seeking Alpha transcript reports that enGene Therapeutics discussed preclinical data and clinical case studies involving incorporation of a surfactant bladder rinse into treatment.

Why it matters — ENGN watchers may note the company’s discussion of preclinical research and clinical case studies related to this treatment approach.

enGene to Host KOL Webinar on October 15, 2026

Business Wire · 13 Oct 2026neutral

enGene Therapeutics announced it will host a webinar on October 15, 2026, at 10:00 a.m. ET. The session will provide more detail on preclinical data supporting the incorporation of its surfactant bladder rinse plus detalimogene into clinical development for BCG-unresponsive, high-risk disease.

Why it matters — The webinar will provide ENGN watchers with additional information about the preclinical data behind this proposed clinical-development approach.

enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 14 Sept 2026neutral

enGene Therapeutics Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation published by Seeking Alpha. The item records the company's participation in the conference.

Why it matters — The conference appearance gives investors and ENGN watchers access to the company's stated updates and commentary on its business outlook.

enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market

Seeking Alpha · 10 Sept 2026neutral

The article discusses enGene Therapeutics' efforts to reduce cash burn, including a 50% workforce reduction that extends its cash runway into 2029, while noting FDA approval risk for its lead asset, detalimogene voraplasmid, due to weak 12-month durability. Management is pursuing a surfactant cohort to address efficacy ahead of pivotal BLA milestones.

Why it matters — ENGN watchers would care because cost-cutting measures could support the company through pivotal regulatory milestones for its lead candidate despite approval risk.

FAQ

Frequently asked questions about ENGN stock

What is the ENGN stock price forecast for 2026-2027?

The 9 Wall Street analysts covering enGene Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ENGN stock a buy right now?

Of the 9 analysts covering enGene Therapeutics, Inc., 3 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks enGene Therapeutics, Inc. 18 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ENGN?

As at 28 Oct 2026, enGene Therapeutics, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (73 of 100).

Will ENGN stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +161.4% from the last close, and Ticker Nerd's factor model ranks enGene Therapeutics, Inc. 18 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ENGN stock forecast for 2030?

No analyst covering enGene Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $5 over the next 12 months.

How has ENGN stock performed over the past year?

enGene Therapeutics, Inc. returned -79.1% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does enGene Therapeutics, Inc. do?

enGene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing non-viral genetic medicines for diseases with significant unmet medical needs.

What is the latest news on ENGN?

The most recent item we track (MarketBeat, 16 Oct 2026): "enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path". enGene used a company webinar to present preclinical findings on investigational non-viral gene therapy detalimogene voraplasmid combined with a polidocanol surfactant bladder rinse. Community urologists also discussed treatment burdens for people with high-risk NMIBC.

Company

About enGene Therapeutics, Inc.

enGene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing non-viral genetic medicines for diseases with significant unmet medical needs. The company’s work centers on its proprietary DDX delivery platform, which is designed to deliver DNA and RNA-based therapies directly to mucosal tissues and other target organs. Its lead product candidate, detalimogene voraplasmid, is being developed as a monotherapy for non-muscle invasive bladder cancer, including difficult-to-treat high-risk cases. enGene Therapeutics Inc. also advances a broader pipeline of gene therapy programs aimed at localized treatment delivery in oncology and other therapeutic areas. Based in Montreal, Canada, the company plays a specialized role in the biotechnology market by pursuing tissue-targeted genetic therapies that seek to address complex diseases through precision delivery approaches.

CEO Mr. Ronald H. W. Cooper · 81 employees · Canada · https://www.engene.com